IP Library Granted Patent US 9,951,093
Granted Patent B2
US 9,951,093 · App. 13/527,217 · Granted Apr 24, 2018

Chiral compounds substituted with phosphonic acid ester functions or phosphonic acid functions

Inventors: Thomas Lindhorst (Innsbruck, AT); Birgit Werner (Innsbruck, AT); Holger Bock (Innsbruck, AT)
Assignee: UGISense AG
C07F9/65121C07K14/003A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,951,093
App. No.
13/527,217
Granted
Apr 24, 2018
Kind
B2
Abstract

The present invention relates to novel compounds that contain PNA units substituted with phosphonic acid ester functions or phosphonic acid functions, and have at least one chiral center. The compounds may be used for the treatment of viral diseases, such as AIDS.

Claims (30)

1. Compound of the formula I,

wherein

n represents an integer from 7 to 35,

each E independently of each other represents a substituted or unsubstituted phenyl group, a substituted or unsubstituted heterocycle, or a nucleobase,

each R 1 independently of each other represents a hydrogen atom or an optionally substituted alkyl, alkenyl, alkylaryl, aryl, heterocyclic or alicyclic group having up to 20 carbon atoms, wherein at least one R 1 is an optionally substituted alkyl, alkenyl, alkylaryl, aryl, heterocyclic or alicyclic group having up to 20 carbon atoms which is substituted with one or more phosphonic acid ester functions or phosphonic acid functions, wherein the phosphonic acid ester functions possess the formula —P(═O)(OV) 2 or —P(═O)(OV)(OH), wherein each V independently of each other represents a methyl, ethyl, cyclohexyl or benzyl group,

K represents a group of the formula —NR 2 R 3 , —N ⊕ R 2 R 3 R 4 , or —NR 2 (CO)R 3 , wherein R 2 , R 3 and R 4 independently of each other represent a hydrogen atom, an alkyl group, amino protecting group, fluorescence marker, chelator, amino acid, peptide, carbohydrate, steroid, fatty acid, or an oligonucleotide, wherein each of the above mentioned groups optionally may be substituted,

L represents a group of the formula —NR 5 R 6 , —NR 5 (CO)R 6 , or —OR 7 , wherein R 5 and R 6 independently of each other represent a hydrogen atom, an alkyl group, fluorescence marker, chelator, amino acid, amino acid amide, peptide, peptide amide, carbohydrate, steroid, fatty acid, or an oligonucleotide, wherein each of the above mentioned groups optionally may be substituted, and wherein R 7 represents a hydrogen atom, an alkyl group, fluorescence marker, chelator, amino acid, peptide, peptide amide, carbohydrate, steroid, fatty acid, or an oligonucleotide, wherein each of the above mentioned groups optionally may be substituted,

wherein the compound of the formula I has 2 to 36 asymmetric centers (*) and 1 to 36 optionally substituted groups R 1 having one or more phosphonic acid ester function(s) or phosphonic acid function(s), and

wherein at least 70% of the number of the asymmetric centers (*) having groups R 1 with one or more phosphonic acid ester function(s) or phosphonic acid function(s) exhibit the R configuration or the S configuration, and at most 40% of the number of the groups R 1 being substituted with phosphonic acid ester functions or phosphonic acid functions.

2. Compound according to claim 1 , wherein each second group R 1 or each third group R 1 independently of each other represents an optionally substituted alkyl, alkenyl, alkylaryl, aryl or alicyclic group having up to 20 carbon atoms, and the remaining groups R 1 represent hydrogen atoms.

3. Compound of formula I,

wherein

n represents an integer from 7 to 35,

each E independently of each other represents a substituted or unsubstituted phenyl group, a substituted or unsubstituted heterocycle, or a nucleobase,

two, three or more adjacent R 1 groups independently of each other represent optionally substituted alkyl, alkenyl, alkylaryl, aryl or alicyclic groups having up to 20 carbon atoms, and the remaining R 1 groups represent hydrogen atoms,

K represents a group of the formula —NR 2 R 3 , —N ⊕ R 2 R 3 R 4 , or —NR 2 (CO)R 3 , wherein R 2 , R 3 and R 4 independently of each other represent a hydrogen atom, an alkyl group, amino protecting group, fluorescence marker, chelator, amino acid, peptide, carbohydrate, steroid, fatty acid, or an oligonucleotide, wherein each of the above mentioned groups optionally may be substituted,

L represents a group of the formula —NR 5 R 6 , —NR 5 (CO)R 6 , or —OR 7 , wherein R 5 and R 6 independently of each other represent a hydrogen atom, an alkyl group, fluorescence marker, chelator, amino acid, amino acid amide, peptide, peptide amide, carbohydrate, steroid, fatty acid, or an oligonucleotide, wherein each of the above mentioned groups optionally may be substituted, and wherein R 7 represents a hydrogen atom, an alkyl group, fluorescence marker, chelator, amino acid, peptide, peptide amide, carbohydrate, steroid, fatty acid, or an oligonucleotide, wherein each of the above mentioned groups optionally may be substituted,

wherein the compound of the formula I has 2 to 36 asymmetric centers (*) and 1 to 36 optionally substituted R 1 groups having one or more phosphonic acid ester function(s) or phosphonic acid function(s), and

wherein at least 70% of the number of the asymmetric centers (*) having R 1 groups with one or more phosphonic acid ester function(s) or phosphonic acid function(s) exhibit the R configuration or the S configuration, and at most 50% of the number of the R 1 groups being substituted with phosphonic acid ester functions or phosphonic acid functions.

4. Compound according to claim 1 , wherein all asymmetric centers (*) have the same configuration.

5. Compound according to claim 1 , wherein all asymmetric centers (*) have a (S) configuration.

6. Compound according to claim 1 , wherein all asymmetric centers (*) have a (R)-configuration.

7. Composition which contains at least one compound according to claim 1 .

8. Pharmaceutical composition, which contains at least one compound according to claim 1 , and, optionally, at least one carrier, solvent or other pharmaceutical adjuvant.

9. Compound according to claim 1 , wherein each of the groups represented by K and L is not substituted.

10. Compound according to claim 3 , wherein each of the groups represented by K and L is not substituted.

11. Compound according to claim 1 , wherein each R 1 independently of each other represents a hydrogen atom or an optionally substituted alkyl or alkenyl group having up to 10 carbon atoms.

12. Compound according to claim 3 , wherein each R 1 independently of each other represents a hydrogen atom or an optionally substituted alkyl or alkenyl group having up to 10 carbon atoms.

13. Compound according to claim 9 , wherein each R 1 independently of each other represents a hydrogen atom or an optionally substituted alkyl or alkenyl group having up to 10 carbon atoms.

14. Compound according to claim 10 , wherein each R 1 independently of each other represents a hydrogen atom or an optionally substituted alkyl or alkenyl group having up to 10 carbon atoms.

Assignments (3)
BANKRUPTCY COURT - INNSBRUCK REGIONAL COURT Recorded Jan 12, 2018
From: UGICHEM GESELLSCHAFT FUR ORGANISCHE CHEMIE MBH
To: UGISENSE AG
Reel/Frame 044620/0806 →
CHANGE OF NAME Recorded Aug 18, 2017
From: UGICHEM GMBH
To: UGICHEM GESELLSCHAFT FUR ORGANISCHE CHEMIE MBH
Reel/Frame 043332/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2017
From: LINDHORST, THOMAS; WERNER, BIRGIT; BOCK, HOLGER
To: UGICHEM GMBH
Reel/Frame 043271/0219 →
Priority Claims (1)
DE 10 2006 034 319 · Jul 21, 2006 · national
Continuity (2)
Continuation 12374440
Related Publication 20130131019A1 · May 23, 2013